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EQ-5d  European quality of Life-5 Dimensions questionnaire 
EQ-VAS European quality of life-visual analogue scale 
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mRS  modified Rankin Scale 
NIHSS  National Institute of Health Stroke Scale 
RCT  Randomised controlled trial 
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ABSTRACT 
 
Background and purpose 
Although poor prognosis after intracerebral haemorrhage relates to risk factors and 
haematoma characteristics, there is limited evidence for the effect of race-ethnicity. 
 
Methods 
Data from 1011 patients with intracerebral haemorrhage enrolled into hyperacute 
trials and randomised to control were obtained from the Virtual International Stroke 
Trials Archive (VISTA) and Efficacy of Nitric Oxide in Stroke (ENOS) Trial. Clinical 
characteristics and functional outcome were compared among three racial groups – 
Asians, Blacks and Caucasians. 
 
Results 
The majority of patients were Caucasian (78.1%) followed by Asians (14.5%) and 
Blacks (5.5%). At baseline, Caucasians were older and had larger haematoma 
volumes; Blacks had lower Glasgow Coma Scale and higher systolic blood pressure 
(all p<0.05). Although the primary outcome of modified Rankin scale (mRS) did not 
differ at 90 days (p=0.14), there were significant differences in mortality 
(p<0.0001) and quality of life (EQ-5D p<0.0001; EQ-VAS p 0.015). In test of 
multiple comparisons, Caucasians were more likely to die (p=0.0003) and had 
worse quality of life  (EQ-5D p=0.003; EQ-VAS p<0.0001) as compared to Asians.  
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Conclusion 
Race-ethnicity appears to explain some of the variation in clinical characteristics 
and outcomes after acute intracerebral haemorrhage. Factors that explain this 
variation need to be identified. 
 
  
Page 6 of 28 
INTRODUCTION 
 
Spontaneous intracerebral haemorrhage (ICH) is a severe cause of stroke 
associated with significant morbidity and mortality.(1) In contrast to ischaemic 
stroke where incidence has declined in recent decades, the number of admissions 
for ICH continues to increase.(2, 3) Variations in ICH incidence and outcome occur 
between different race-ethnicity groups. A higher incidence of ICH is observed 
among black and Hispanic populations when compared with Caucasians.(4-6) The 
SINO-MONICA-Beijing study reported greater mortality due to ICH in China 
compared to other countries.(7) Death caused by stroke was reported to be higher 
in Asians compared to Caucasian patients in the UK and Canada.(8, 9) The causes 
for these observations are unclear and might be explained by increased prevalence 
of risk factors such as diabetes and hypertension among Asians.(10-13) Additional 
explanatory factors also appear to include blood pressure at presentation.(5, 14-
16) However, studies assessing ICH in different race-ethnicity groups have mostly 
involved small centres with limited numbers of patients, and have restricted 
comparisons to differences between two racial populations.(5, 6, 17, 18) 
 
In this study, we compared baseline clinical characteristics and functional outcome 
in three racial groups in patients with ICH. The data came from the Virtual 
International Stroke Trials Archive (VISTA) collaboration,(19) and the Efficacy of 
Nitric Oxide in Stroke (ENOS) trial.(20) 
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Methods 
  
Data sources 
Included patients came from the VISTA-ICH archive, which includes data from a 
number of completed randomised controlled trials,(19) and the acute ENOS blood 
pressure trial.(20, 21) Patients were those with spontaneous ICH, as diagnosed 
locally using routine neuroimaging, and who were treated within 6 hours of onset. 
We included patients allocated to the control group in ENOS, as patients assigned 
to intervention are not included in VISTA. Patients were excluded if: age<18, ICH 
attributed to trauma, planned surgical evacuation, previously dependent (mRS >2), 
concurrent illness with life expectancy <6 months, pregnant or breast feeding 
women, and those already participating in a study involving another drug or device. 
 
Baseline data 
Data at baseline were obtained for age, sex, time from ictus to treatment, medical 
history (previous stroke, hypertension, ischaemic heart disease, diabetes mellitus, 
hypercholesterolemia, atrial fibrillation, and prior antithrombotic use), level of 
consciousness (Glasgow Coma Scale, GCS), stroke severity (National Institutes of 
Health Stroke Scale, NIHSS), systolic blood pressure (SBP), and heart rate. Race 
(and ethnicity) was defined as Asian (Filipino, Oriental, Asian, Indian, Palestinian 
and Arabic), Black (black, African/American, Caribbean), Caucasian (white or 
Caucasian) and Others (American Indian, mixed-coloured, mixed, Hispanic, 
coloured, Hawaiian and Pacific Islanders). 
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Outcome data 
Outcome at day 90 was assessed using the modified Rankin scale (mRS) and all 
cause mortality; where available, data on disability (Barthel Index, BI) and quality 
of life (Euro-QoL, EQ-5D) were also assessed.  
 
Neuroimaging 
Depending on trial protocol, CT scans were performed following treatment and then 
again at 72 hours. Information from CT scans was collected for haemorrhage 
location, lesion volume, oedema volume, presence of mass effect, subarachnoid 
bleeding, intraventricular haemorrhage, brain atrophy and leukoaraiosis. 
 
 
Statistical analysis 
The primary outcome was the mRS at day 90. Baseline characteristics and 
outcomes were compared by Pearson χ2 test for categorical variables, and analysis 
of variance for continuous variables. The relationship between baseline haematoma 
volume and mRS between ethnic groups was analysed using multiple regression. 
Individual comparisons between ethnic groups were made using Bonferroni 
correction. Mortality was assessed using Kaplan-Meier curves and Cox Regression. 
Analyses were adjusted for age, NIHSS, ICH volume and time to treatment. 
Confidentiality agreements precluded identification of the individual trials in VISTA-
ICH and so analyses were not adjusted for trial. Since death is present in outcome 
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scores such as mRS (6), HUS (0) and BI (-5), death was scored for EQ-VAS as -1. 
Statistical significance was set at p<0.05. All analyses were performed using SPSS 
(version 21) running on an Apple Mac computer. 
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RESULTS 
 
Baseline clinical and neuroimaging characteristics 
A total of 1011 patients were identified: 979 recruited from VISTA-ICH,(19) and 32 
from ENOS.(20) The mean age was 66.2 years, 63.2% were male, the average 
time to treatment was 3.7 hours, and the mean GCS was 13.8 (Table 1). The 
majority of patients were Caucasian (78.1%), followed by Asians (14.5%) and 
Blacks. Less than 2% were in the ‘other group’ and these were removed from 
further analyses. When analysed by baseline characteristics, Black patients were 
younger and more likely to have a previous history of hypertension and higher SBP 
at baseline. Caucasian patients trended to have more atrial fibrillation, and Asian 
patients were less likely to have a prior history of antithrombotic use. The mean 
ICH volume was 22.7 cm3 and most haematomas were located in the deep 
subcortical white matter of the brain (Table 1). 
 
Clinical outcomes 
Table 2 shows clinical and radiological outcome measures by ethnicity. The primary 
outcome, mRS, did not differ between race groups at either day 7 or 90 (Figure 1). 
Similarly, there was no difference in NIHSS during the first 7 days. Whilst the 
Barthel Index differed at 7 days, it was not significant at day 90 using a test of 
multiple comparisons. Quality of life, assessed using two measures (health utility 
status derived from EQ-5D, and EQ-VAS), differed between the three groups (Table 
2, Figure 2); following adjustment for multiple comparisons, Caucasians had a 
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worse quality of life scores for both EQ-5D and EQ-VAS as compared to Asians 
(Table 2). Adjusted survival rates differed between race-ethnicity groups (Table 2, 
Figure 3), explained by a significant difference between Asians and Caucasians 
(p=0.005). There were no other significant differences for other outcomes. 
 
Neuroimaging outcomes 
ICH volume differed across the race groups on both the first follow-up scan (Table 
2, Figure 4) and at 72 hours. (Table 2); in both cases, Caucasians tended to have 
larger haematoma (Table 2). Similarly, oedema volumes differed across the race 
groups on both the first follow-up scan and at day 7 with Caucasian patients have 
large oedema volumes than Black patients. The presence of hydrocephalus also 
differed and was highest in Caucasians. The presence of intraventricular 
haemorrhage, subarachnoid haemorrhage and midline shift did not differ between 
the race groups (Table 2). 
 
When assessing the relationship between baseline haematoma volume and mRS, 
there was a significant difference in the slope of the regression lines between the 
race-ethnicity groups; blacks and Asians appeared to have a worse mRS for a given 
haematoma volume (p=0.047; Supplementary Figure 1). There were no other 
significant differences between any of the other comparison groups.  
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DISCUSSION 
 
To our knowledge, this is the first study to examine clinical and neuroimaging 
features and outcomes in ICH patients across three race groups. Significant 
differences in age, the frequency or previous stroke and hypertension, Glasgow 
coma scale, blood pressure and ICH volume were present between Caucasian, 
Asian and black patients. Similarly, differences in neuroimaging features were 
present for haematoma location and volume, oedema volume, and the presence of 
subarachnoid haemorrhage, hydrocephalus, leukoaraiosis and cerebral atrophy. 
Although there was no difference in the primary outcome of mRS at day 90, 
significant differences in case fatality and quality of life were present. Similarly, 
differences in ICH and oedema volume, and the presence of hydrocephalus, were 
present between the race groups.  
 
Black patients were younger and a larger proportion had a history of hypertension 
which could be associated with increased smoking, alcohol and drug abuse.(17, 18) 
It is noteworthy that BP in blacks was higher on admission and probably reflects 
inadequate control, poor compliance with treatment or treatment resistance.(17, 
22) One study assessing race-ethnic BP differences ICH reported similar findings 
but the comparison groups were different.(23) Higher BP in the acute phase of ICH 
is common (24) and associated with neurological deterioration through haematoma 
expansion and re-bleeding.(24-26) The treatment implications of racial difference in 
BP lowering need investigation as evidence suggests that early treatment is both 
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safe and feasible,(20, 27) and is now recommended in guidelines.(28, 29) In 
contrast to a previous report of greater mortality in blacks for every stroke 
subtype,(30) VISTA-ENOS found reduced survival in Caucasians with ICH. This 
finding is difficult to explain and may relate to haemorrhage location, inherent 
susceptibility to ICH or quality of care or simply that race-ethnic differences persist 
even after controlling for such characteristics.  
 
As would be expected, ICH survivors had a quality of life worse than that reported 
in the general population.(31, 32) The difference between Caucasians and Asians 
has been reported previously,(14, 33) and may relate to family values, cultural 
attitudes and care preferences.(33, 34) In one study, Asians were more likely to be 
living at home whilst Caucasians were less likely to be discharged home despite 
better functional improvement.(35) Apart from cultural and family factors, age, 
female sex, stroke severity, persistent neglect and socioeconomic status have also 
been shown to affect quality of life after stroke.(36, 37)  
 
The strengths of the study include a relatively large sample size for a study 
population with detailed clinical, radiological information and multiple functional 
endpoints. The included patients were from neutral RCT’s or control group and 
therefore assessment of the race-ethnic differences avoided the confounding effects 
of active treatment. However, there are some limitations. First, the analysis on 
observational data from RCT’s has the disadvantage that patients were included on 
the basis of pre-specified selection criteria. It is possible that those with more 
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severe stroke with reduced level of consciousness, older patients with multiple 
comorbidities and pre-existing do not resuscitate orders may have been excluded. 
Therefore, the results may not be applicable to a population of unselected ICH 
patients. Second, the VISTA collaboration does not reveal the identities of the 
individual trials and so it is uncertain as to what inclusion criteria were used to 
select patients. Additionally, analyses could not be adjusted for the source trials, 
which is important since trials themselves are a determinant of outcome. 
Nevertheless, the data were subject to strict verification and so the results are 
externally valid. Third, ethnicity relates to culture, geography, language and it is 
not clear from the data if this was self-reported or defined by the investigator. 
Fourth, to compensate for limited numbers, distinct subpopulations were grouped 
into one ethnic group (for example Asians included people from China, Philippines, 
the Indian subcontinent, and Arabian peninsula) whilst small groups, present in the 
‘others’ category were excluded. This may have not been appropriate as stroke risk 
and functional outcome vary within subpopulations living in the same country and 
between countries.(38, 39) Last, the analysis is limited to trials sharing information 
within the collaboration and therefore those studies that are not represented in 
VISTA would not have been included. 
 
In conclusion, this analysis from hyperacute trials in haemorrhagic stroke found 
significant race differences in baseline clinical characteristics and haematoma 
measures. There were no difference in the primary outcome of death or 
dependency but differences in death rates and quality of life were apparent. Further 
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studies are needed to which factors explain race-ethnic differences and whether 
these differences become larger over time. Our results suggest that future trials 
should undertake measures to ensure adequate representation of all major race-
ethnic groups. This might include standard definitions for race-ethnicity that reflect 
common features but not limited to, biological, cultural and social differences. 
Further research is also needed to understand where inadequacies in health care 
systems exist and what interventions can be made to reduce such disparities. This 
could include allowing more resources to developing countries or those without 
access to specialist stroke care teams.  
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Table 1. Baseline characteristics of 1011 patients with intracerebral haemorrhage by ethnicity.  Data are number (%) or mean 
(standard deviation). Comparisons by chi-square test or one-way analysis of variance. 
 
Demographics n All Caucasian Asian Black Other 2p 
C v A 
2p 
C v B 
2p 
A v B 
2p 
Number of patients (%)  1011 790 (78.1) 147 (14.5) 56 (5.5) 18 (1.8)     
Clinical findings  
 
 
     
   
Age (years) 1011 66.2 (12.5) 67.7 (12.1) 61.3 (12.5) 58.4 (11.3) 61.9 (11.0) <0.001 <0.0001 <0.0001 0.13 
Sex, male (%) 982 621 (63.2) 489 (63.3) 40 (65.6) 32 (57.1) 10 (71.4) 0.56 0.64 0.39 0.33 
OTT (hrs) 1007 3.7 (1.2) 3.7 (1.2) 3.6 (1.4) 3.4 (1.2) 3.7 (1.2) 0.08 0.26 0.035 <0.0001 
Medical history           
   Previous stroke (%) 1011 106 (10.5) 71 (9.0) 24 (16.3) 8 (14.3) 3 (16.7) 0.017 0.011 0.23 0.83 
   Hypertension (%) 1011 813 (80.4) 613 (77.6) 133 (90.5) 52 (92.9) 15 (83.3) <0.0001 <0.0001 0.006 0.78 
   IHD (%) 1011 105 (10.4) 92 (11.6) 10 (6.8) 3 (5.4) 0 (0) 0.07 0.11 0.19 1.00 
   Diabetes mellitus (%) 1011 177 (17.5) 135 (17.1) 25 (17.0) 11 (19.6) 6 (33.3) 0.89 1.00 0.59 0.68 
   HC (%) 997 49 (4.8) 43 (5.4) 5 (3.4) 1 (1.8) 0 (0) 0.49 0.40 0.42 1.00 
   Atrial fibrillation (%) 1011 68 (6.7) 62 (7.8) 4 (2.7) 2 (3.6) 0 (0) 0.047 0.022 0.43 0.67 
   Antithrombotic(s) (%) 162 162 (16.0) 143 (18.1) 8 (5.4) 7 (12.5) 4 (22.2) 0.005 1.00 0.77 0.87 
NIHSS (/42) † 1008 13.7 (1.9) 13.7 (5.6) 13.3 (6.0) 15.1 (7.4) 13.7 (1.9) 0.12 0.37 0.08 0.07 
GCS (/15) 1010 13.8 (1.8) 13.8 (1.8) 13.4 (1.9) 13.2 (2.2) 14.1 (1.7) 0.010 0.037 0.015 0.37 
Systolic BP (mmHg) 1008 174.4 (29.2) 173.1 (29.3) 176.7 (26.5) 185.7 (40.0) 174.4 (29.2) 0.005 0.18 0.002 0.041 
Diastolic BP (mmHg) 1007 93.2 (19.0) 91.6 (18.5) 97.1 (18.5) 106.0 (21.1) 93.8 (20.8) <0.001 0.001 <0.0001 0.003 
Heart rate (bpm) 1005 80.0 (15.1) 78.1 (15.4) 76.6 (13.8) 79.9 (14.6) 78.2 (14.1)     0.34     0.27 0.40 0.14 
Neuroimaging           
Haematoma location (%)           
   Lobar 863 134 (13.3) 122 (15.4) 5 (3.4) 7 (12.5) 0 0.001 <0.0001 0.57 0.045 
   Subcortical white matter 893 685 (67.8) 541 (68.5) 93 (63.3) 42 (75.0) 9 (50.0) 0.006 0.30 0.73 0.34 
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   Thalamus 600 217 (21.5) 181 (22.9) 22 (15.0) 10 (17.9) 4 (22.2) 1.00 1.00 1.00 1.00 
   Brain stem/cerebellum 893 21 (2.1) 17 (2.2) 2 (1.4) 1 (1.8) 1 (5.6) 0.82 0.75 1.00 1.00 
Haematoma volume (cm3) 996 22.7 (23.1) 24.2 (24.9) 17.8 (13.1) 15.8 (14.1) 18.5 (17.3) 0.005 0.03 0.014 0.34 
Oedema volume (cm3) 874 13.9 (15.7) 14.9 (16.9) 11.1 (9.2) 9.9 (10.4) 8.1 (7.8) 0.007 0.015 0.041 0.48 
Midline shift (%) 885 623 (61.6) 488 (61.8) 90 (61.2) 38 (67.9) 7 (38.9) 0.62 0.67 0.43 0.71 
SAH (%) 1007 80 (7.9) 73 (9.2) 3 (2.0) 1 (1.8) 3 (16.7) 0.003 0.02 0.05 1.00 
IVH (%) 876 286 (28.3) 234 (29.6) 33 (22.4) 17 (30.4) 2 (11.1) 0.22 0.14 0.75 0.26 
Hydrocephalus (%) 860 619 (61.2) 517 (65.4) 64 (43.5) 29 (51.8) 9 (50.0) <0.001 <0.0001 0.004 0.74 
Leukoaraiosis (%) 619 287 (28.4) 251 (31.8) 21 (14.3) 12 (21.4) 3 (21.4) 0.28 0.29 0.18 0.66 
Cerebral atrophy (%) 1007 552 (54.6) 469 (59.4) 50 (34.0) 21 (37.5) 12 (66.7) <0.001 <0.0001 0.002 0.74 
 
† Calculated (40) from Scandinavian Stroke Scale in ENOS 
BP: blood pressure; GCS: Glasgow Coma Scale; HC: hypercholesterolemia; IHD: ischaemic heart disease; IVH: intraventricular 
haemorrhage; OTT: onset to treatment; SAH: subarachnoid haemorrhage 
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Table 2. Clinical and radiological outcomes by race groups. Data are number (%) and mean (standard deviation). Comparisons 
between group differences made by chi-square test or analysis of variance; multiple comparisons include Bonferroni correction. 
 
 n All Caucasian Asian        Black Other 2p C v A C v B A v B 
Patients  1011 790 147 56 18  2p 2p 2p 
Clinical           
mRS (/6)           
   Day 7 538 4.1 (1.1) 4.2 (1.1) 4.2 (0.8) 3.9 (1.3) 4.6 (0.5) 0.36 1.00 0.07 0.12 
   Day 90 873 3.2 (1.6) 3.2 (1.6) 3.0 (1.6) 3.4 (1.7) 3.1 (1.8) 0.14 0.18 1.00 0.37 
NIHSS (/42) †           
   Day 1 936 13.1 (7.0) 13.1 (7.0) 12.8 (6.7) 13.2 (8.1) 12.4 (6.5) 0.89 1.00 1.00 1.00 
   Day 3 564 12.5 (8.0) 12.7 (8.2) 11.0 (6.3) 11.6 (8.3) 14.8 (7.0) 0.29 0.42 1.00 1.00 
   Day 7 534 10.8 (7.1)  10.9 (7.9) 10.2 (6.1) 10.7 (7.5) 13.1 (6.7) 0.80 1.00 1.00 1.00 
   Day 90 958 8.1 (9.8) 8.1 (10.1) 6.0 (5.7) 9.6 (10.4) 9.7 (10.6) 0.31 0.88 0.96 0.41 
Barthel Index (/100)           
   Day 7 539 28.9 (31.1) 28.6 (31.2) 30.6 (29.1) 33.9 (36.5) 14.4 (16.1) 0.010 1.00 1.00 1.00 
   Day 90 872 63.0 (37.4) 62.9 (37.6) 66.0 (35.7) 56.4 (39.0) 66.5 (39.1) 0.28 1.00 0.68 0.34 
Day 90           
   Death (%) 1011 211 (20.9) 189 (23.3) 11 (7.5) 9 (16.1) 2 (11.1) <0.001 <0.001 0.59 0.33 
   EQ-5D (/1) 487 0.29 (0.37) 0.25 (0.36) 0.46 (0.40) 0.31 (0.40) 0.40 (0.39) <0.001 <0.001 1.00 0.18 
   EQ-VAS (/100) 321 46.0 (33.5) 43.3 (33.6) 57.0 (30.2) 44.2 (35.2) 42.5 (60.1) 0.015 0.012 1.00 0.34 
Neuroimaging           
ICH vol. (cm3)           
   Follow up scan 523 32.3 (32.2) 34.7 (34.4) 26.2 (23.8) 23.7 (23.6) 18.9 (24.1) 0.017 0.07 0.14 1.00 
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   72 hours 930 27.3 (28.6) 28.7 (30.4) 23.3 (19.7) 20.1 (20.3) 21.6 (20.4) 0.019 0.13 0.09 1.00 
Oedema vol. (cm3)           
   Follow up scan 428 31.8 (31.8) 34.1 (33.9) 29.1 (25.7) 19.7 (20.8) 19.7 (18.4) 0.030 0.65 0.038 0.46 
   72 hours 924 33.6 (30.9) 33.6 (30.9) 29.9 (22.1) 22.0 (19.6) 24.8 (23.4) 0.009 0.53 0.012 0.26 
IVH (%)           
   Follow up scan 399 195 (19.3) 145 (18.4) 35 (23.8) 14 (25.0) 1 (5.6) 0.98 0.90 1.00 1.00 
   72 hours 811 344 (34.0) 277 (35.1) 46 (31.3) 19 (33.9) 2 (11.1) 0.41 0.54 0.55 1.00 
72 hours           
   SAH (%) 566 97 (9.6) 87 (11.0) 7 (4.8) 2 (3.6) 1 (5.6) 0.23 0.21 0.20 0.71 
   Hydrocephalus (%) 791 605 (59.8) 498 (63.0) 67 (45.6) 31 (55.4) 9 (50.0)  <0.001 <0.001 0.016 0.60 
   Midline shift (%) 790 628 (62.1) 490 (62.0) 94 (63.9) 37 (66.1) 7 (38.9) 0.54 0.25 0.72 0.37 
A: Asians; B: Blacks; C: Caucasians; EQ-5D: European Quality of Life-5 dimensions; EQ-VAS: European Quality of Life-Visual 
Analogue Scale; ICH: intracerebral haemorrhage; IVH: intraventricular haemorrhage; mRS: modified Rankin scale; NIHSS: 
National Institutes of Health Stroke Scale; SAH: subarachnoid haemorrhage 
†Calculated from Scandinavian Stroke Scale in the ENOS trial (40) 
Range of scores for patients in ENOS: 
Barthel Index: -5 (death) to 0 (severe disability) to 100 (no disability). 
Health utility status (HUS, derived from European Quality of Life-5 dimensions, EQ-5D): -0.5 (very poor quality of life, 0 (death) to 
1.0 (perfect quality of life). European Quality of Life-Visual Analogue Scale (EQ-VAS): -1 (death), 0 (very poor) to 100 (excellent). 
Zung Depression Scale (ZDS): 0 (normal), 100 (severe depression) to 102.5 (death) 
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Figure 1. Distribution of modified Rankin scores between the three race 
groups at day 90.  
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Figure 2. Box plots of Euro Quality of Life-5Dimension-3 level scores at day 
90. Comparison by ANOVA 2p<0.001; Caucasian vs Asian 2p<0.001, 
Caucasian vs Black 1.00, Asian vs Black 2p=0.18. 
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Figure 3. Cox regression with adjustment for age, baseline systolic blood 
pressure, stroke severity (NIHSS), haematoma volume and time to 
treatment: overall p=0.021; Asians vs Caucasians, hazard ratio 0.42 (95% 
CI 0.22, 0.77); p=0.005. 
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Figure 4.  Intracerebral haematoma volume on first follow-up imaging by 
race. Comparison by ANOVA 2p=0.017; Caucasian vs Asian 2p=0.07, 
Caucasian vs black 0.14, Asian vs black 2p=1.0. 
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Supplementary Figure 1. Relationship between haematoma volume at baseline 
and functional outcome, assessed as the modified Rankin Scale (mRS), at day 90 
for Caucasians, Asians and Blacks. The continuous and dotted lines indicate the 
regression lines. 
 
 
 
Overall comparison between the three ethnicities (using ANCOVA) showed a 
difference in the slopes of the regression lines between the three groups 
(p<0.0001). Individual comparisons found significant difference in the slopes of the 
regression lines between Blacks vs Asians (p=0.047; using Bonferroni correction). 
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There were no significant differences between any of the other ethnic group 
comparisons. Analysis was adjusted for age, baseline NIHSS, ICH volume and time 
to treatment. 
 
 
